Search Results

71 - 80 of 82 items :

  • pharmacokinetics x
  • Life Sciences x
Clear All
Procedural Sedation and Analgesia in Adults - new trends in patients safety

. Pharmacokinetic and Pharmacodynamic Characteristics of Medications Used for Moderate Sedation. Clinical Pharmacokinetics. 2006; 45(9):855-869. 27. Mueller S, Moore G, MacLaren R. Fospropofol Disodium for Procedural Sedation: Emerging Evidence of its Value?. Clinical Medicine Insights: Therapeutics. 2010; 2:1179559X1000200. 28. Bellolio MF, Gilani W, Barrionuevo P, et al. Incidence of Adverse Events in Adults Undergoing Procedural Sedation in the Emergency Department: A Systematic Review and Meta-analysis. Academic Emergency Medicine. 2016; 23(2): 119–134. 29

Open access
Spatial relationship between the c-Fos distribution and enkephalinergic, substance P, and tyrosine hydroxylase innervation fields after acute treatment with neuroleptics olanzapine, amisulpride, quetiapine, and aripiprazole in the rat septum

, Barlow KB, Nobrega JN, Kapur S. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. Int J Neuropsychopharmacol 14, 1165–1178, 2011. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63 (Suppl 13), 5–11, 2002. Nomikos GG, Tham CS, Fibiger HC, Svensson TH. The puta in rat medial prefrontal cortex and lateral tive atypical antipsychotic drug amperozide preferentially increases c-fos expression septum

Open access
Retrospection of the effect of hydroxyurea treatment in patients with sickle cell disease

pharmacokinetics of HU indicate that the renal impairment results in increased systemic exposure and decreased urinary recovery of the drug [ 16 ]. Some patients receiving HU therapy showed mild albuminuria, with an increase in white cells and granular casts, as well as occasional red cells, in the urine [ 76 ]. However, the BABY HUG trial demonstrated that HU is associated with better urine-concentrating ability and less renal enlargement, in addition to improvement in overall renal function [ 58 ]. Studies in animal models revealed that that HU therapy inhibits spermatogenesis

Open access
New Drug Delivery Systems Concept in Anaesthesia and Intensive Care—Controlled Release of Active Compounds

Surg 2008; 6:57-63 52. Ilfeld BM, Malhotra N, Furnish TJ, Donohue MC, Madison SJ. Liposomal bupivacaine as a single-injection peripheral nerve block: a dose-response study. Anesth Analg 2013; 117:1248-1256 53. Viscusi ER, Candiotti KA, Onel E, Morren M, Ludbrook GL. The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. Reg Anesth Pain Med 2012; 37:616-622 54. Tsuchiya H, Ueno T, Mizogami M, Takakura K. Local anesthetics structure

Open access
New Drug Delivery Systems Concept in Anaesthesia and Intensive Care—Controlled Release of Active Compounds

pain after iliac bone harvesting: a randomised controlled trial. Int J Surg 2008; 6:57-63 52. Ilfeld BM, Malhotra N, Furnish TJ, Donohue MC, Madison SJ. Liposomal bupivacaine as a single-injection peripheral nerve block: a dose-response study. Anesth Analg 2013; 117:1248-1256 53. Viscusi ER, Candiotti KA, Onel E, Morren M, Ludbrook GL. The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. Reg Anesth Pain Med 2012; 37:616-622 54. Tsuchiya H, Ueno T, Mizogami M, Takakura K

Open access
Zastosowanie infuzyjnego schematu chemioterapii DA-EPOCH w leczeniu chłoniaków agresywnych

] schedule, and pharmacokinetics would improve outcome in patients with large B-cell lymphomas. A prospective multi-institutional study of administration of etoposide, vincristine, and doxorubicin for 96 hours with bolus doses of cyclophosphamide and oral prednisone (EPOCH therapy. Schemat chemioterapii EPOCH z podaniem leków w dawkach dostosowywanych, z lub bez dodatku rituximabu (DA-EPOCH(-R), dose adjusted -EPOCH - rituximab) jest leczeniem wykorzystującym długotrwałą infuzję cytostatyków, z modyfikacją dawek w kolejnych cyklach na podstawie obserwowanych parametrow

Open access
Progressive arthropathy in the course of immune tolerance induction failure in a child with hemophilia A and FVIII inhibitor – a case report

with hemophilia A with inhibitors: results from the HAVEN 2 study Blood 2018 132 suppl 1 632 (abstr) [13] Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019. Published online April 16, 2019. Pipe SW Shima M Lehle M et al Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre

Open access
Implantoprosthetic rehabilitation of a patient with severe form of hemophilia B: a case report

subcommittee of factor VIII and factor IX of the scientific and standarization committee of the International Society on Thrombosis and Haemostasis Thromb Haemost. 2001 85 560 [4] Lehmann-Kopydlowska M, Zawilska K. Dental guidelines in congenital hemophilia A and B. Czas Stomatol. 2010;63(6):345-357. Lehmann-Kopydlowska M Zawilska K. Dental guidelines in congenital hemophilia A and B Czas Stomatol. 2010 63 6 345 357 [5] Bjorkman S, Carlsson M, Berntop E. Pharmacokinetics of factor IX in patients with haemophilia B: Methodological aspects and physiological interpretation

Open access
Stosowanie leków biopodobnych w hematoonkologii – stanowisko Polskiego Towarzystwa Hematologów i Transfuzjologów

Kanakasetty GB et al Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study Lancet Haematol 2017 4 e350 61 [8] Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017;4:e362

Open access
A short review of primary aldosteronism in a question and answer fashion

, Lim RC, Siperstein AE, Clark OH, Schecter WP, Hunt TK, Horn JK, Duh QY. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Arch Surg 134, 628-632, 1999. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10, 23-29, 2005. So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI, Stowasser M. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J

Open access